Shionogi Secures Complete Ownership of Global Rights to RADICAVA (edaravone) Shionogi & Co., Ltd. has announced the successful completion of a major strategic transaction involving the full transfer of rights to RADICAVA (edaravone), marking a significant milestone in the company’s…
Bristol Myers Squibb Strengthens and Expands Commitment to Advancing Equitable Care in Multiple Myeloma as GAAP Initiative Reaches Ten Years Bristol Myers Squibb (NYSE: BMY), a recognized leader in oncology, has announced a significant evolution of its long-standing “Standing in…
Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Accelerate Development of Next-Generation Lymphedema Care Technology Sub-Q Bionics, an emerging innovator in the medical device space, has taken a significant step forward in its mission to transform care for patients living…
WuXi Biologics Earns CDMO Leadership Awards for the Ninth Straight Year WuXi Biologics has once again reinforced its leadership position in the global biologics outsourcing sector, announcing that it has been named “Biologics CDMO of the Year” in the Large…
CorVista Health Unveils Machine Learning–Driven Noninvasive Approach to Detect Cardiac Ischemia at ACC.26 CorVista Health has announced promising new clinical data supporting a novel, noninvasive diagnostic approach for detecting cardiac ischemia using physiologic signal analysis combined with advanced machine learning.…
LEO Pharma Showcases New Real-World Data on Tralokinumab at AAD 2026, Highlighting Benefits Across Diverse Atopic Dermatitis Populations LEO Pharma has presented new post-hoc analyses from its ongoing TRACE study, offering important real-world insights into the effectiveness of tralokinumab in…
Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based drug discovery, has announced a new strategic collaboration with Taisho…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the sustained safety and efficacy of povorcitinib (INCB54707), an investigational oral,…
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data demonstrating that its biologic therapy EBGLYSS (lebrikizumab-lbkz) can deliver sustained…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care analytics and a KLAS-rated, HITRUST-certified solution, has announced its expanded…
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively participating in the 2026 Phoenix Heart Walk, taking place on…
Allergan Aesthetics Introduces Next-Generation Hyaluronic Acid Injectables with JUVÉDERM at AMWC Monaco Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and has announced that…